Cardiol Therapeutics (CRDL)

Executive Summary

Cardiol Therapeutics (TSX: CRDL) is a clinical-stage biotechnology company focused on developing novel therapies for heart disease by targeting inflammation and fibrosis. Its lead candidate, CardiolRx™, is a pharmaceutical-grade cannabidiol formulation being investigated in two Phase II trials: MAvERIC-Pilot for recurrent pericarditis and ARCHER for acute myocarditis following myocardial infarction. These conditions represent significant unmet medical needs with limited treatment options, positioning CardiolRx as a potential first-in-class therapy. The company's science leverages cannabidiol's anti-inflammatory and anti-fibrotic properties, which have shown promise in preclinical models and early-phase studies. As of mid-2026, both trials are ongoing, with MAvERIC-Pilot expected to report top-line data later this year and ARCHER data anticipated in early 2027. Positive results could validate CardiolRx's therapeutic potential and drive significant value, given the large addressable markets. However, clinical-stage biotech carries inherent risks, including regulatory hurdles and competition from existing treatments like colchicine and IL-1 inhibitors. Cardiol's cash runway and ability to fund further development remain key factors. Overall, the company represents a high-risk, high-reward opportunity in the cardiovascular space, with catalysts that could trigger substantial re-rating.

Upcoming Catalysts (preview)

• Q3 2026MAvERIC-Pilot Phase II top-line data for recurrent pericarditis55% success
• Q1 2027ARCHER Phase II interim or top-line data for acute myocarditis50% success
• TBDPotential partnership or licensing agreement for CardiolRx30% success